Lung Neuroendocrine Carcinoma — Trials

Lung Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 389
Recruiting: 206
Ph III recruiting: 27
Growth YoY: −1%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (158)

clinicaltrialsPublishedShowing 101–105 of 105 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06008353	A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil(EDUR-BRA)	active not recruiting	—	60	AstraZenecaINDUSTRY	1	Dec 19, 2024	clinicaltrials
NCT05879068	A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC	active not recruiting	Phase 2	99	Biotheus Inc.INDUSTRY